» Articles » PMID: 9870205

One-methyl Group Metabolism in Non-ketotic Hyperglycinaemia: Mildly Elevated Cerebrospinal Fluid Homocysteine Levels

Overview
Publisher Wiley
Date 1998 Dec 31
PMID 9870205
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Non-ketotic hyperglycinaemia (NKH) is a rare, severe brain disease caused by deficient glycine cleavage enzyme complex activity resulting in elevated glycine concentrations. Recent experience suggests that factors in addition to glycine kinetics are involved in its pathogenesis. The glycine cleavage reaction through the formation of methylenetetrahydrofolate is an important one-methyl group donor. A deficiency in one-methyl group metabolites, in particular of choline, has been hypothesized in NKH. We investigated metabolites involved in one-methyl group metabolism in plasma and CSF of 8 patients with NKH, and monitored the effect of treatment with choline in one patient. Plasma and CSF choline and phosphatidylcholine concentrations were normal, except for a low plasma choline in the single neonate studied. Choline treatment did not change brain choline content, and was not associated with clinical or radiological improvement. Methionine concentrations and, in one-patient, S-adenosylmethionine and 5-methyltetrahydrofolate concentrations were normal in CSF. Homocysteine concentrations in CSF, however, were slightly but consistently elevated in all four patients examined, but cysteine, cysteinylglycine and glutathione were normal. Serine is important in the transfer of one-methyl groups from mitochondria to cytosol. Serine concentrations were normal in plasma and CSF, but dropped to below normal in CSF in three patients on benzoate treatment. These observations add to our understanding of the complex metabolic disturbances in NKH.

Citing Articles

Cerebrospinal fluid amino acids glycine, serine, and threonine in nonketotic hyperglycinemia.

Swanson M, Miller K, Young S, Tong S, Ghaloul-Gonzalez L, Neira-Fresneda J J Inherit Metab Dis. 2022; 45(4):734-747.

PMID: 35357708 PMC: 9543955. DOI: 10.1002/jimd.12500.


Biomarkers of Nutrition for Development-Folate Review.

Bailey L, Stover P, McNulty H, Fenech M, Gregory 3rd J, Mills J J Nutr. 2015; 145(7):1636S-1680S.

PMID: 26451605 PMC: 4478945. DOI: 10.3945/jn.114.206599.


Glycine decarboxylase deficiency causes neural tube defects and features of non-ketotic hyperglycinemia in mice.

Pai Y, Leung K, Savery D, Hutchin T, Prunty H, Heales S Nat Commun. 2015; 6:6388.

PMID: 25736695 PMC: 4366506. DOI: 10.1038/ncomms7388.


Polymorphisms in 1-carbon metabolism, epigenetics and folate-related pathologies.

Stover P J Nutrigenet Nutrigenomics. 2012; 4(5):293-305.

PMID: 22353665 PMC: 3696357. DOI: 10.1159/000334586.


A mathematical model gives insights into the effects of vitamin B-6 deficiency on 1-carbon and glutathione metabolism.

Nijhout H, Gregory J, Fitzpatrick C, Cho E, Lamers K, Ulrich C J Nutr. 2009; 139(4):784-91.

PMID: 19244383 PMC: 2666368. DOI: 10.3945/jn.109.104265.


References
1.
Speilberg S, Lucky A, Schulman J, KRAMER L, Hefner L, Goodman S . Letter: Failure of Leucovorin therapy in nonketotic hyperglycinemia. J Pediatr. 1976; 89(4):681-2. DOI: 10.1016/s0022-3476(76)80421-0. View

2.
Klein J, Koppen A, Loffelholz K . Small rises in plasma choline reverse the negative arteriovenous difference of brain choline. J Neurochem. 1990; 55(4):1231-6. DOI: 10.1111/j.1471-4159.1990.tb03129.x. View

3.
Van Hove J, Kishnani P, Muenzer J, Wenstrup R, Summar M, Brummond M . Benzoate therapy and carnitine deficiency in non-ketotic hyperglycinemia. Am J Med Genet. 1995; 59(4):444-53. DOI: 10.1002/ajmg.1320590410. View

4.
Trauner D, Page T, Greco C, Sweetman L, Kulovich S, Nyhan W . Progressive neurodegenerative disorder in a patient with nonketotic hyperglycinemia. J Pediatr. 1981; 98(2):272-5. DOI: 10.1016/s0022-3476(81)80659-2. View

5.
Quinn C, Griener J, Bottiglieri T, Hyland K, Farrow A, Kamen B . Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. J Clin Oncol. 1997; 15(8):2800-6. DOI: 10.1200/JCO.1997.15.8.2800. View